Scientific Programme of the CELCC 2020

(as of November 18, 2020. The programme is continuously updated)

Friday, November 27

Opening session
Luboš Petruželka, Czech Republic
Robert Pirker, Austria
Gyula Ostoros, Hungary
12:30 – 12:35 Opening remarks Luboš Petruželka, Czech Republic
12:35 – 13:00 Statistics in clinical trials and medical research Ondřej Májek, Czech Republic
13:00 – 13:10 Discussion  

Session I:

Early detection in clinical practice & research
Gyula Ostoros, Hungary
Jiří Votruba, Czech Republic
13:10 – 13:30 Management of small lung nodules Helmut Prosch, Austria
13:30 – 13:50 Circulating biomarkers in early detection and treatment of lung cancer – sponsored by Sotio Filip Janků, USA
13:50 – 14:10

Pilot screening project in the Czech Republic

– sponsored by AstraZeneca

Jiří Votruba, Czech Republic
14:10 – 14:30 Experience with screening in Croatia Ante Marušić, Croatia
14:30 – 14:50 HUNCHEST screening in Hungary Anna Kerpel-Fronius, Hungary
14:50 – 15:10 Panel discussion  
Break 15:10 – 15:40    
Satellite symposium I 15:40 – 16:40
Break 16:40 – 16:50    

Session II:

Precision diagnosis of lung cancer 


David Zogala, Czech Republic

16:50 – 17:15 Artificial intelligence in imaging Lukáš Lambert, Czech Republic
17:15 – 17:40 New technologies in imaging David Zogala, Czech Republic
17:40 – 18:05 Next generation sequencing in diagnosis: indications and utilization rate Jószef Tímár, Hungary
18:05 – 18:30

Predictive biomarkers for the treatment of NSCLC

Kristýna Němejcová, Czech Republic
approx. 5 minutes of Q & A section is a part of each lecture in this session
Special session:

Petr Zatloukal Memorial lecture

18:30 – 19:00 Conquering lung cancer in Central Europe Jean Klastersky, Belgium

Saturday, November 28

Session III:
Therapy of early stage lung cancer 
Stanislav Trča, Czech Republic

Renata Soumarová, Czech Republic


8:30 – 8:55Minimally invasive surgeryMir Alireza Hoda, Austria
8:55 – 9:20

Proton radiotherapy in early stage of lung cancer treatment

Jiří Kubeš, Czech Republic
9:20 – 9:45Stereotactic radiotherapy of  NSCLCJakub Cvek, Czech Republic
9:45 – 10:10The role of radiotherapy fractionationKarin Dieckmann, Austria
approx. 5 minutes of Q & A section is a part of each lecture in this session
Break10:10 – 10:40  

Session IV:

Trimodality therapy of locally advanced NSCLC – current status and perspectives 
Milada Zemanová, Czech Republic
sponsored by AstraZeneca
10:40 – 11:00

Care of patients with Non-Small-Cell lung cancer stage III – the Central European real-world experience – final analysis

– sponsored by AstraZeneca

Milada Zemanová, Czech Republic
11:00 – 11:20

Patient case study: tratment variability in N2 positive stage III NSCLC

Daniel Krejčí, Czech Republic
11:20 – 11:40Adjuvant therapy of resected NSCLCRobert Pirker, Austria
11:40 – 12:00Induction therapy followed by surgery in NSCLCRenata Soumarová, Czech Republic
12:00 – 12:20Definitive chemoradiotherapyJacek Jassem, Poland
12:20 – 12:40Panel discussion 
Satellite symposium II.13:10 – 14:10
 Bristol-Myers Squibb
Break14:10 – 14:20  
Session V:
Immunotherapy of metastatic lung cancer – current evidence
Luboš Petruželka, Czech Republic
Leona Koubková, Czech Republic
sponsored by MSD
14:20 – 14:40Immunotherapy beyond checkpoint inhibitorsRadek Špíšek, Czech Republic
14:40 – 15:00Atezolizumab in metastatic lung cancer – current evidenceLibor Havel, Czech Republic
15:00 – 15:20Durvalumab (metastatic non small cell lung cancer)Gyula Ostoros, Hungary
15:20 – 15:40NivolumabHelena Linardou, Greece
15:40 – 16:00PembrolizumabLuboš Petruželka, Czech Republic
16:00 – 16:20Panel discussion 
Break16:20 – 16:50  
Session VI:
Targeted therapies of mutation-positive NSCLC


Jana Skřičková, Czech Republic

Miloš Pešek, Czech Republic

16:50 – 17:15EGFR mutation-positive NSCLC: recent advancesKrisztina Bogos, Hungary
17:15 – 17:40ALK-positive NSCLC: recent advancesPeter Beržinec, Slovakia
17:40 – 18:05Liquid biopsy for disease monitoringMartin Filipits, Austria
18:05 – 18:30Novel targets and drugsNir Peled, Israel
approx. 5 minutes of Q & A section is a part of each lecture in this session

Sunday, November 29

12:20 – 12:30Poster presentation 4TBA

  Board: radiologist Andrea Burgetová, General Univ. Hospital, pathologist Radoslav Matěj, Thomayer Hospital, medical oncologists Milada Zemanová and Luboš Petruželka, General Univ. Hospital, radiation oncologists Soňa Argalácsová, General Univ. Hospital, surgeon Jan Kolařík, Univ. Hospital Motol, pneumologist Helena Čoupková, Masaryk Memorial Cancer Institute
Session VII:
Multidisciplinary tumor board – locally advanced / metastatic NSCLC, 3 cases

 Robert Pirker, Austria

Martin Svatoň, Czech Republic

9:00 – 9:30 Agressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment – a case report Martin Svatoň, Czech Republic
9:30 – 10:00 Multidisciplinary management in stage III NSCLC Thomas Klikovits, Austria
10:00 – 10:30 Successful multivariate treatment of stage IV EGFR Exon-19 mutant pulmonary adenocarcinoma Gabriella Gálffy, Hungary
Break 10:30 – 11:00    
Session VIII:
SCLC, Mesothelioma and best posters presentation


Nevena Secen, Serbia

Helena Čoupková, Czech Republic

11:00 – 11:25 Small cell lung cancer: treatment advances Nevena Sečen, Serbia
11:25 – 11:50 Malignant pleural mesothelioma: treatment advances Marko Jakopović, Croatia
11:50 – 12:00

Poster presentation –

Definitive chemoradiotherapy of locally advanced Non-Small Cell Lung Cancer (LA-NSCLC) with IGRT technique using tomotherapy HD – updated asnalysis
Stanislav Hloušek et all., Czech Republic
12:00 – 12:10

Poster presentation –

The role of serum tumour markers in the detection of malignant lung tumours
Martin Skála et all., Czech Republic
12:10 – 12:20

Poster presentation –

Impact of concomitant medication administered at the time of initiation of the outcome of nivolumab therapy in Non-Small Cell Lung Cancer

Martin Svatoň et all., Czech Republic
12:20 – 12:30

Poster presentation –

Examination of the immune cells profile of NSCLC patients indicated for inhibitory checkpoint immunotherapy

Jan Špaček et all., Czech Republic

approx. 5 minutes of Q & A section is a part of each lecture in this session

Closing Remarks
12:30 – 13:00